Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1998-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.83.4.4742PMID 9543129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proximal femur bone mineral levels of US adults

  2005cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management

  2000cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• Altered trabecular architecture induced by Corticosteroids: A Bone Histomorphometric Study

  1996cited by this paper
• Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

  1996cited by this paper
• Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.

  1996cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines.

  1996cited by this paper
• Interpreting trials of bone-active agents.

  1995cited by this paper
• Rheumatoid arthritis, corticosteroid therapy and hip fracture.

  1995cited by this paper
• Intact parathyroid hormone levels are not elevated in glucocorticoid‐treated subjects

  1995cited by this paper
• Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

  1995cited by this paper
• Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

  1995cited by this paper
• Bone loss after heart transplantation: a prospective study.

  1994cited by this paper
• Mechanisms of rapid bone loss following cardiac transplantation

  1994cited by this paper
• Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.

  1994cited by this paper
• High‐dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton

  1994cited by this paper
• Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

  1994cited by this paper
• Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylprednisolone.

  1994cited by this paper
• Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis.

  1993cited by this paper
• Bone metabolism in rheumatoid arthritis; relation to disease activity.

  1993cited by this paper
• Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity.

  1993cited by this paper
• Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis

  1993cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography.

  1992cited by this paper
• Diagnosis of Osteoporosis

  1992influential reference
• Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

  1991cited by this paper
• The course of biochemical parameters of bone turnover during treatment with corticosteroids.

  1991cited by this paper
• Corticosteroid effects on proximal femur bone loss

  1990cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro

  1990cited by this paper
• Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders.

  1990cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Perspectives bone histomorphometry in glucocorticoid‐induced osteoporosis

  1989cited by this paper
• Determination of bone Gla protein (osteocalcin) by enzyme-linked immunosorbent assay.

  1989cited by this paper
• Appropriate use of bone densitometry.

  1989cited by this paper
• Bone histomorphometry in glucocorticoid-induced osteoporosis.

  1989cited by this paper
• Glucocorticoids increase parathyroid hormone receptors in rat osteoblastic osteosarcoma cells (ROS 17/2)

  1988cited by this paper
• Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.

  1988cited by this paper
• Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis.

  1988cited by this paper
• Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells.

  1986cited by this paper
• Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids.

  1986cited by this paper
• The effects of monocyte-conditioned medium and interleukin 1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone cells in vitro.

  1984cited by this paper
• Fractures after rheumatoid arthritis. A population-based study.

  1984cited by this paper
• Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome.

  1984cited by this paper
• Steroid-induced fractures and bone loss in patients with asthma.

  1983cited by this paper
• An interleukin 1 like factor stimulates bone resorption in vitro

  1983cited by this paper
• Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.

  1983cited by this paper
• Long-term therapy of Paget's disease of bone with EHDP.

  1980cited by this paper
• Glucocorticoid potentiation of the adenosin 3',5'-monophosphate response to parathyroid hormone in cultured rat bone cells.

  1978cited by this paper
• Calcium and phosphorus homeostasis in man. Effect of corticosteroids.

  1976cited by this paper

• In Vitro and In Vivo Pharmacological Profiles of DS‐1211, a Novel Potent, Selective, and Orally Bioavailable Tissue‐Nonspecific Alkaline Phosphatase Inhibitor

  2022cites this paper
• Glucocorticoid-induced osteoporosis and Cushing’s syndrome

  2021cites this paper
• Basic and clinical aspects of glucocorticoid action in bone

  2020cites this paper
• Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials

  2020cites this paper
• Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis

  2019cites this paper
• Metabolic Bone Disease in Gastrointestinal Disorders

  2019cites this paper
• 2 . Paraplegia related bone impairment

  2017cites this paper
• Bisphosphonates for steroid-induced osteoporosis.

  2016cites this paper
• One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy

  2016cites this paper
• Glucocorticoid-induced Osteoporosis.

  2016cites this paper
• Safety Assessment of Etidronic Acid and Salts of Etidronic Acid as Used in Cosmetics

  2016cites this paper
• Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis

  2016cites this paper
• Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials

  2016cites this paper
• Chapter 12 – Pharmacology and Drug Therapy: Nonbiologic Therapies

  2016cites this paper
• Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros

  2015cites this paper
• Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk

  2015cites this paper
• Glucocorticoids and bone: local effects and systemic implications.

  2014cites this paper
• Paraplegia Related Osteoporosis

  2014cites this paper
• 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis.

  2014cites this paper
• Actualisation 2014 des recommandations sur la prévention et le traitement de l'ostéoporose cortico-induite

  2014cites this paper
• Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

  2014cites this paper
• Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability.

  2013cites this paper
• Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

  2013cites this paper
• Les bisphosphonates dans l’ostéoporose cortico-induite : efficacité et tolérance

  2013cites this paper
• Chapter 49 – Glucocorticoid-Induced Osteoporosis

  2013cites this paper
• Alendronate

  2012cites this paper
• Management of Glucocorticoid-Induced Osteoporosis

  2012cites this paper
• Corticosteroid-Induced Osteoporosis

  2012cites this paper
• Hip Fracture Prevention

  2012cites this paper
• Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

  2012cites this paper
• A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

  2012cites this paper
• Farmakoterapijski savjetnik Advices in pharmacotherapy

  2011cites this paper
• 7 – Principles and Guidelines of Immunotherapy in Neuromuscular Disorders

  2011cites this paper
• Osteoporosis: burden, health care provision and opportunities in the EU

  2011cites this paper
• Prescription for antiresorptive therapy in Mexican patients with rheumatoid arthritis: is it time to reevaluate the strategies for osteoporosis prevention?

  2011cites this paper
• Osteoporosis inducida por corticoides

  2011cites this paper
• PHARMACOLOGY AND DRUG THERAPY

  2011cites this paper
• Selecting the optimal treatment for glucocorticoid-induced osteoporosis.

  2011cites this paper
• Glucocorticoid-Induced Osteoporosis: A Review

  2010cites this paper
• Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

  2010influential citation
• International Encyclopedia of Rehabilitation

  2010cites this paper
• L’ostéoporose : une pratique en mouvement☆

  2010cites this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cites this paper
• Metabolic Bone Disease in Gastrointestinal Disorders

  2010cites this paper
• 16. Metabolic Bone Disease in Gastrointestinal Disorders

  2010cites this paper
• The safety of bisphosphonate use in pre-menopausal women on corticosteroids.

  2009cites this paper
• Glucocorticoids and the risk of osteoporosis

  2009cites this paper
• Glucocorticoid-induced osteoporosis: treatment update and review

  2009cites this paper
• Bone health in systemic lupus erythematosus

  2009cites this paper
• KAPITEL 11 – Transplantation

  2008cites this paper
• Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians

  2008cites this paper
• Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna

  2008cites this paper
• Etude de la densité minérale osseuse par absorptiomètre biphotonique chez les asthmatiques sous corticoïdes inhales

  2008cites this paper
• Skeletal effects of systemic and topical corticosteroids.

  2008cites this paper
• Tratamento Farmacológico da Osteoporose em Portugal

  2008cites this paper
• [Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].

  2008cites this paper
• CHAPTER 44 – Glucocorticoid-Induced Osteoporosis

  2008cites this paper
• Risk factors, prevention, and treatment of corticosteroid-induced osteoporosis in adults.

  2008cites this paper
• Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates

  2007cites this paper
• The International Hormone Society

  2007cites this paper
• Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

  2007cites this paper
• Bisphosphonates in Corticosteroid-Induced Osteoporosis

  2007cites this paper
• La patologia ossea nel paziente trapiantato renale

  2007cites this paper
• Prévention et traitement de l'ostéoporose cortico-induite

  2007cites this paper
• Corticotrophins, Corticosteroids and Prostaglandins

  2007cites this paper
• Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures

  2006cites this paper
• The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis.

  2006cites this paper
• The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis

  2006cites this paper
• Glucocorticoid-induced osteoporosis and its treatment.

  2006influential citation
• Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment

  2006cites this paper
• Prévention et traitement de l'ostéoporose cortico-induite

  2006cites this paper
• Ostéopathies endocriniennes (en dehors de l'hyperparathyroïdie)

  2006cites this paper
• Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia

  2006cites this paper
• [Prevention and treatment of steroid-induced osteoporosis].

  2006cites this paper
• Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach.

  2006cites this paper
• Prise en charge de l’ostéoporose cortisonique

  2006cites this paper
• Practice patterns in patients at risk for glucocorticoid-induced osteoporosis

  2005cites this paper
• Prise en charge de l'ostoporose cortisonique en 2005

  2005cites this paper
• Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.

  2005cites this paper
• Improvement of Reduced Bone Mineral Density by Intermittent Cyclical Etidronate in Postmenopausal Asthmatic Patients Receiving Inhaled Corticosteroids

  2005cites this paper
• Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.

  2005cites this paper
• Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis

  2005cites this paper
• In whom and how to prevent glucocorticoid-induced osteoporosis.

  2005cites this paper
• Anti-resorptive therapy for the prevention of postmenopausal osteoporosis : when should treatment begin?

  2005cites this paper
• Osteoporosis associated with excess glucocorticoids.

  2005cites this paper
• Bisphosphonates for osteoporosis prevention and treatment

  2005cites this paper
• The Climacteric and Osteoporosis in Women with Autoimmune Diseases

  2005cites this paper
• Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club

  2005cites this paper
• L’osteoporosi indotta da corticosteroidi

  2005cites this paper
• Ostéoporose cortisonique: prévention et traitement

  2004cites this paper
• Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids

  2004cites this paper
• Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.

  2004cites this paper
• 91 – Corticosteroid-Induced Osteoporosis: A Comprehensive Review

  2004cites this paper
• The treatment of glucocorticoid-induced osteoporosis.

  2004cites this paper
• Risk factors for osteoporosis in female patients with systemic lupus erythematosus

  2004cites this paper
• L’ostéoporose cortisonique

  2004cites this paper
• 46 – CORTICOSTEROID USE IN SYSTEMIC LUPUS ERYTHEMATOSUS

  2004cites this paper
• [Corticosteroid-induced osteoporosis].

  2004cites this paper
• Prevention and treatment of nonpostmenopausal osteoporosis.

  2004cites this paper
• Osteoporosis en la Enfermedad Pulmonar Obstructiva Crónica

  2004influential citation